within Pharmacolibrary.Drugs.ATC.L;

model L01XX78
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.34,
    Cl             = 0.06833333333333333,
    adminDuration  = 600,
    adminMass      = 0.15,
    adminCount     = 1,
    Vd             = 0.271,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005666666666666667,
    Tlag           = 36.0
  );

  annotation(Documentation(
    info ="<html><body><p>Navitoclax is a small-molecule, orally bioavailable inhibitor of the anti-apoptotic Bcl-2 family of proteins, including Bcl-2, Bcl-xL, and Bcl-w. It is investigated as an anticancer agent due to its ability to induce apoptosis in cancer cells. It is not widely approved for clinical use and is mostly used in clinical trials for hematologic malignancies and some solid tumors.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with cancer following oral administration of navitoclax, single-dose and multiple-dose, in phase I clinical trials.</p><h4>References</h4><ol><li><p>Salem, AH, et al., &amp; Xiong, H (2014). Effect of co-administration of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety and tolerability of navitoclax, a first-in-class oral Bcl-2 family inhibitor, in cancer patients. <i>Anticancer research</i> 34(4) 2001–2006. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24692738/&quot;>https://pubmed.ncbi.nlm.nih.gov/24692738</a></p></li><li><p>Tolcher, AW, et al., &amp; Rosen, LS (2015). Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors. <i>Cancer chemotherapy and pharmacology</i> 76(5) 1025–1032. DOI:<a href=&quot;https://doi.org/10.1007/s00280-015-2883-8&quot;>10.1007/s00280-015-2883-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26420235/&quot;>https://pubmed.ncbi.nlm.nih.gov/26420235</a></p></li><li><p>Tolcher, AW, et al., &amp; Rosen, LS (2015). Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study. <i>Cancer chemotherapy and pharmacology</i> 76(5) 1041–1049. DOI:<a href=&quot;https://doi.org/10.1007/s00280-015-2882-9&quot;>10.1007/s00280-015-2882-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26429709/&quot;>https://pubmed.ncbi.nlm.nih.gov/26429709</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01XX78;
